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Abstract
Mapping the molecular circuits that are perturbed by genetic variants underlying complex traits 
and diseases remains a great challenge. We present a comprehensive resource of 394 cell type and 
tissue-specific gene regulatory networks for human, each specifying the genome-wide connectivity 
between transcription factors, enhancers, promoters and genes. Integration with 37 genome-wide 
association studies (GWASs) shows that disease-associated genetic variants — including variants 
that do not reach genome-wide significance — often perturb regulatory modules that are highly 
specific to disease-relevant cell types or tissues. Our resource opens the door to systematic 
analysis of regulatory programs across hundreds of human cell types and tissues.
Introduction
Genome-wide association studies (GWASs) have successfully identified thousands of 
genetic loci associated with complex traits and diseases. However, translating these findings 
into a functional understanding of disease processes remains a major challenge, notably 
because the effect of individual trait-associated variants is typically minute, underlying 
mechanisms are generally cell type-specific1–3, and most variants lie in poorly understood 
noncoding regions of the genome4.
Integration of regulatory genomics data is emerging as a promising strategy to address these 
challenges: it has been shown that GWAS variants enrich in regulatory regions of cell types 
that are relevant to the pathophysiological basis of a given trait5,6, and regulatory 
annotations have been used to prioritize and fine-map GWAS loci7–9. However, these studies 
do not consider the inter-play between variants at the pathway and network level. Pathway- 
and network-based approaches, on the other hand, have been successful at identifying 
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relevant pathways or modules based on the connectivity between trait-associated genes, but 
current studies typically rely on protein-protein interaction10,11, co-expression12 or 
functional association networks13 lacking fine-grained regulatory and, with few 
exceptions14–16, tissue-specific information. Indeed, a suitable compendium of tissue-
specific regulatory circuits was previously not available, as most studies focused on building 
gene regulatory networks either globally17–19 or for a single tissue or condition of in 
terest20–22.
Here we introduce a unique resource of 394 cell type and tissue-specific gene regulatory 
networks for human. We infer networks by integrating transcription factor (TF) sequence 
motifs with promoter and enhancer activity data from the FANTOM5 project23,24 (Fig. 1a,b) 
and validate edges using ChIP-seq, eQTL and RNA-seq data. We find that GWAS variants 
often perturb genes that are clustered within specialized regulatory circuits of trait-relevant 
tissues (Fig. 1c). While previous studies have established the value of disease-specific gene 
networks25, the present resource of 394 regulatory circuits enables systematic analysis of the 
fine-scale mechanism of driver genes across cell types and tissues. All networks and tools 
are freely available at: http://regulatorycircuits.org.
Results
Cell type and tissue-specific gene regulatory circuits
Our pipeline to reconstruct transcriptional regulatory circuits involves: (1) genome-wide 
mapping of promoters and enhancers, (2) linking TFs to promoters and enhancers, and (3) 
linking enhancers and promoters to target genes (Fig. 1a, Methods). Here, we applied this 
approach to data from the FANTOM5 consortium23,24, which has performed cap analysis of 
gene expression (CAGE) for ~1000 human primary cell, tissue and cell line samples. CAGE 
maps regions of transcription initiation with high resolution and sensitivity, enabling the 
identification of both active promoters and enhancers (active enhancers are transcribed at 
low levels, resulting in a CAGE signature of bidirectional transcription initiation24). In order 
to identify regulatory inputs of promoters and enhancers, we used a curated collection of 
sequence binding motifs for 662 TFs26,27. We found >10-fold enrichment of these TF motifs 
within CAGE-defined promoters and distal enhancers, supporting the FANTOM5 data 
(Methods, Supplementary Figs. 1–3).
We used this pipeline to infer 394 weighted, transcriptional regulatory circuits, including 
146 different cell types, 111 tissues, and 137 cell lines (Supplementary Table 1, 
Supplementary Figs. 4–5). Each circuit has up to 662 TFs, 41K enhancers, 59K promoters, 
and 43K gene isoforms from 19K protein-coding genes. Enhancers and promoters are 
regulated by a median number of 16 TFs, and on average gene isoforms receive inputs from 
two distinct promoters and five enhancers (Supplementary Figs. 6–8).
Validation of regulatory circuits using independent ChIP-seq, eQTL and RNA-seq data
While systematic validation of our regulatory circuits is difficult because the ground truth is 
not known28, independent datasets that support regulatory edges are available for a subset of 
cell lines and tissues. First, we assessed the inferred TF–enhancer and TF–promoter edges 
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using TF binding data (ChIP-seq) for 59 TFs in five cell lines from ENCODE 
(Supplementary Table 2). Overall, about half of the TF edges were confirmed by a 
corresponding ChIP-seq peak, which is not far off the reproducibility of the ChIP-seq data 
themselves (Fig. 2a, Supplementary Figs. 9–10).
Second, we assessed enhancer–gene edges of our circuits in 13 tissues where eQTL data 
were available from GTEx29 (Supplementary Table 3, Methods). Overall, about one third of 
the enhancer–gene edges in our circuits were confirmed by a cis-eQTL, outperforming 
alternative approaches such as assigning enhancers to the closest or most strongly correlated 
target gene (Fig. 2b, Supplementary Figs. 11–12).
Lastly, we sought to evaluate whether the regulatory circuits are predictive of gene 
expression levels. To this end, we obtained RNA-seq data for 40 matching tissues from the 
Roadmap Epigenomics project30 (Supplementary Table 4). We indeed found a strong 
correlation between the TF input of a gene (defined as the sum of its incoming edge weights) 
and its expression level in a given tissue (Methods, Supplementary Fig. 13).
Network architecture reflects developmental and functional relationships among cell types 
and tissues
Having evaluated the accuracy of our circuits, we next sought to compare regulatory 
programs of genes across lineages. To this end, we defined for each regulatory circuit a 
corresponding coarse-grained network, summarizing TF inputs at the level of genes (Fig. 1b, 
Methods). We hierarchically clustered these networks based on edge overlap (Methods). As 
expected, developmentally and functionally related lineages were consistently grouped 
together, indicating that they share regulatory components (Supplementary Figs. 14–24). 
Analysis of network architecture showed that immune cells, followed by cells and tissues of 
the nervous system, have the highest number of TFs per gene, while other network 
properties are comparable across lineages (Supplementary Figs. 25–26).
GWAS variants perturb regulatory modules in disease-relevant cell types and tissues
In order to systematically evaluate the relevance of tissue-specific regulatory networks for a 
broad range of traits and diseases, we compiled a large panel of 37 GWASs (Supplementary 
Table 5) and assessed whether trait-associated variants perturb genes that cluster in network 
modules (connectivity enrichment analysis, Fig. 1c and Methods). To reduce the burden of 
multiple testing (394 networks × 37 GWASs), we first considered 32 high-level networks 
derived from the hierarchical clustering described above. (Networks in the same cluster were 
merged). We found that the majority of GWAS traits show stronger connectivity enrichment 
in tissue-specific regulatory networks than in protein interaction, co-expression and ChIP-
based networks (Fig. 2c). Moreover, connectivity enrichment often extended to weakly 
associated genes that did not pass the GWAS significance threshold (Supplementary Fig. 
31b).
Next, we asked whether the observed clustering of perturbed genes was specific to 
regulatory networks of trait-relevant tissues. We examined all GWAS traits that showed 
connectivity enrichment in at least one network (score > 1.0 in Fig. 2c) and ranked the 32 
high-level networks by their enrichment score. Networks of disease-relevant cell types and 
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tissues consistently ranked at the top, thus showing the strongest evidence for perturbed 
modules. For example, the psychiatric, cross-disorder study showed the strongest clustering 
of associated genes precisely in the three high-level networks of nervous system and brain, 
schizophrenia in the two networks specific to adult brain, and anorexia nervosa in networks 
of the endocrine system followed by nervous system and hindbrain, suggesting that 
endocrine dysregulation, a hallmark of chronic starvation in anorexia nervosa31, may be 
implicated (Fig. 3a).
Going one step further, for all high-level networks that showed connectivity enrichment, we 
also assessed the individual cell type and tissue-specific networks pertaining to the 
corresponding clusters. For example, within the two adult brain clusters that showed signal 
for schizophrenia, we found the strongest clustering of perturbed genes in components of the 
basal ganglia, which modulate motor, cognitive and emotional behavior (Fig. 3a). The 
dopaminergic system of the basal ganglia manifests pathological anomalies in schizophrenia 
patients and is the primary target of current antipsychotic drugs32. This example 
demonstrates that perturbed regulatory modules can pinpoint disease-relevant tissues with 
remarkable precision.
We made similar observations for the remaining traits (Supplementary Figs. 32–43). The 
psychiatric cross-disorder study showed strong clustering of perturbed genes in regulatory 
networks of the caudate nucleus, thalamus, locus coeruleus, and other core structures 
underlying cognitive and emotional functions that are impaired in psychiatric disorders 
(Supplementary Fig. 33). For bipolar disorder, the amygdala, a group of brain nuclei key to 
memory, experienced emotions, and mood that has been consistently implicated in 
etiological models of bipolar disorder33, ranked first (Supplementary Fig. 34). Inflammatory 
bowel disease showed strong connectivity enrichment in endothelial cells, which are 
gatekeepers of inflammatory processes targeted by current drugs34, as well as immune cells 
and tissues involved in pathogenesis (spleen, monocytes and mast cells35,36; Fig. 3b). For 
rheumatoid arthritis, the strongest clustering of perturbed genes was found in neutrophils, 
which have an activated phenotype in patients and contribute to pathogenesis37 
(Supplementary Fig. 37). For Alzheimer's disease, the strongest clustering of associated 
genes occurred in regulatory networks of adult forebrain followed by endothelial cells, 
suggesting that neurovascular dysregulation may be implicated38 (Fig. 3c, Supplementary 
Fig. 38). Narcolepsy, a rare sleep disorder caused by autoimmune targeting of hypocretin-
producing neurons39, shows connectivity enrichment in neural stem cells (Supplementary 
Fig. 39). Body mass index (BMI) shows the strongest clustering of perturbed genes in 
regulatory networks of the intestinal tract and immune system, thus suggesting a potential 
link with the gut microbiome, which has recently been proposed to have a heritable 
component that impacts BMI40 (Supplementary Fig. 42). Finally, of the two subtypes of age-
related macular degeneration, only the neovascular type caused by abnormal blood vessel 
growth showed network connectivity enrichment in vascular smooth muscle cells, consistent 
with their function in neovascularization (Fig. 3d).
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Discussion
Lately, there has been growing interest in tissue-specific gene networks for understanding 
human physiology and disease14–16. The present resource of 394 regulatory circuits 
dramatically expands the number of cell types and tissues for which networks are available, 
and it is the first collection of fine-grained regulatory circuits connecting TFs, enhancers, 
promoters, and gene isoforms in human.
The FANTOM5 enhancers and promoters underlying our networks have been previously 
validated23,24 and the observed enrichment for the independently curated TF motifs provides 
further support. In addition, we validated the inferred tissue-specific edges using indpendent 
ChIP-seq, eQTL and RNA-seq data, in each case finding good support. Of note, TF motifs 
alone are known to have low specificity for predicting TF binding, as we confirmed. Key to 
our approach is that we require both a TF motif and activity of the corresponding regulatory 
element to infer an edge in a given tissue. Implicitly, this approach also accounts for co-
factors on which the TF may be dependent for binding at a specific regulatory element: if 
co-factors or other conditions to activate the TF are not present, the regulatory element is not 
active and thus no edge would be added in this tissue, explaining the high specificity of our 
circuits.
Genetic association data provide an orthogonal means of validation: our systematic analysis 
across 37 GWASs showed that perturbed regulatory modules often pinpoint cell types and 
tissues that are known to be involved in pathophysiological processes, and in some cases are 
targets of current medications, with remarkable precision. For most traits, evidence of 
increased connectivity between perturbed genes extended to variants that did not pass the 
genome-wide significance threshold, indicating that regulatory network information will be 
useful for prioritizing candidate variants.
Our analysis of network architecture showed that similarity between regulatory networks 
closely reflects developmental or functional relationships between respective cell types and 
tissues, suggesting that phenotypic relatedness results from shared circuit components. 
Identifying and functionally characterizing these components is an important avenue for 
future work. We also found variability in network architecture across different lineages, with 
regulatory networks of the immune and nervous system having by far the most TF inputs per 
gene. Both immune cells and neurons perform highly adaptive functions. Our networks 
suggest that the orchestration of transcriptional responses in these cells involves intricate 
regulatory programs. Interestingly, the high number of TF inputs (i.e., binding sites) also 
makes these genes more likely to be perturbed by regulatory variants, which suggests that 
immune and neural processes may be particularly prone to genetic dysregulation. This 
proposition is further supported by the strong network connectivity enrichment that we 
observed for immune-related, psychiatric, and neurodegenerative disorders. Tissue-specific 
regulatory networks may thus be key to understanding the etiology of these disorders.
We did not yet attempt to infer causal variants in the context of our circuits. This is a 
difficult task because a given GWAS locus often spans multiple genes and regulatory 
regions, harboring many potentially causal variants. To this end, a probabilistic graphical 
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model applied to 127 reference epigenomes recently showed promising results (Quon et al., 
in preparation). Another challenge is to characterize perturbed pathways and their role in 
disease processes, which will be extremely valuable for biomarker and drug discovery. We 
make our networks along with user-friendly software tools freely available and hope that this 
resource will spur the development of additional methods capable of integrating large 
collections of networks to identify disease-relevant tissues and dissect the regulatory 
architecture of complex traits.
Methods
Inference of cell type and tissue-specific regulatory networks
We represent transcriptional regulatory networks as graphs, which include four different 
types of nodes: TFs, enhancers, promoters, and gene isoforms. Directed, weighted edges 
connect TFs to enhancers and promoters, and enhancers and promotes to gene isoforms. 
Regulatory circuit inference involves defining the nodes and the edges for each of these 
layers. To this end, we developed a pipeline consisting of four steps.
The first step is to map regulatory elements (promoters and enhancers) and their tissue-
specific activity. Both chromatin-state and CAGE-defined maps can be used for this purpose. 
Here, we used the CAGE-defined maps from the FANTOM5 project because they currently 
cover the largest number of human cell and tissue types (~1000 samples compared to 127 
epigenomes available from the ENCODE43 and Roadmap Epigenomics30 projects). First, we 
obtained the FANTOM5 set of 184,827 robust CAGE peaks and their activity levels across 
all samples (RLE normalized expression profiles)23. These CAGE peaks represent high-
confidence regions of transcription initiation; we refer to them as CAGE-defined promoters 
(note that the full promoter region where TFs bind extends beyond these peaks, as described 
below). Second, we obtained the FANTOM5 set of 43,012 CAGE-defined enhancers and 
their activity levels across all samples (RLE normalized expression profiles)24. These 
enhancers have been identified based on enhancer RNAs (eRNAs) that are detectable 
through a robust signature of weak, bi-directional transcription in CAGE data24,44. After 
discarding samples that were not present in either the promoter or expression data, we were 
left with 808 cell and tissue samples, which formed the basis for regulatory circuit 
reconstruction (Supplementary Table 1).
The second step is to link TFs to promoters and enhancers. To this end, we used a curated 
collection of sequence binding motifs (position weight matrices) for 662 TFs provided by 
Kheradpour et al., where each motif occurrence in the genome (referred to as a motif 
instance) was further assigned a confidence score based on it's evolutionary conservation 
across mammals26,27,45. Based on our positional enrichment analysis (described in the next 
section), we determined that motif instances are >10-fold enriched in a window 400bp 
upstream to 50bp downstream of CAGE-defined promoters (Supplementary Fig. 1). We thus 
linked TFs to CAGE-defined promoters based on the occurrence of TF motif instances 
within these windows (of note, since the bulk of the motif instances are located around the 
TSS (see distribution in Supplementary Fig. 1a), the cutoff at 10-fold enrichment is not a 
critical parameter: using a less stringent cutoff expands the windows but adds only a small 
fraction of edges to the networks). The weight of TF–promoter edges was defined as the 
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confidence score of the corresponding TF motif instance (if multiple motif instances of the 
same TF were found in a given window, the maximum confidence score was taken). The 
exact same approach was used to link TFs to enhancers, the only difference being that the 
window where motif instances were >10-fold enriched coincided with the CAGE-defined 
enhancers, i.e., it did not extend up or downstream. Edge weights were defined in the same 
way as for TF–promoter links.
The third step is to link CAGE-defined promoters to known gene isoforms. We used the 
Ensembl genome annotation, comprising 53,449 isoforms from 19,125 protein-coding genes 
(accessed May 31st, 2014). Note that the isoforms, not the genes, constitute nodes of our 
circuits. This is because different isoforms of the same gene often have distinct transcription 
start sites (TSSs) that are under control of independent promoters, which may have different 
regulatory inputs and tissue-specific activity. We linked CAGE-defined promoters to TSSs of 
gene isoforms using the exact same approach as described above: we determined that 
CAGE-defined promoters enrich >10-fold in a window 250bp upstream to 500bp 
downstream around TSSs and linked promoters within these windows to the corresponding 
gene isoforms. The weight of promoter–gene edges was defined as the normalized activity 
level of the promoter across all samples (normalization was done per regulatory element 
because expression levels of diverse enhancers and promoters may not be on the same 
scale). Thus, if the promoter is not active in a given cell type, the edge weight is zero (i.e., 
the edge is not present), and if the promoter is maximally active, the edge weight equals one.
The fourth step is to link enhancers to their target gene isoforms, which is more challenging 
because enhancers are often distal and their targets may be cell type-specific1,3. We opted 
for a parsimonious approach weighting potential enhancer–isoform links based on just two 
factors: their genomic distance and activity level in the given tissue. The weighting function 
for the distance was derived directly from the distance distribution of known cis-eQTLs 
from their target genes. To this end, we obtained 38,935 high-confidence cis-eQTLs from 
RegulomeDB46, computed their distance from the TSS of their target genes, and defined the 
weighting function as a smooth fit of the resulting distance distribution (we used local 
polynomial regression fitting). The weighting function was defined for the range [1kb, 
500kb] and scaled to give a maximum weight of one; enhancers at a distance of <1kb and 
>500kb were assigned weights of one and zero, respectively (Supplementary Fig. 1d). This 
implies that enhancer–isoform interactions over more than 500kb were not included in our 
networks. However, the cis-eQTL distribution shows that this is only a minor fraction of all 
interactions (Supplementary Fig. 1d, less than 6% of cis-eQTLs are located over 500kb away 
from their target gene) and our correlation analysis suggests that these long-range 
interactions would be difficult to identify from CAGE data alone (Supplementary Figs. 2, 3). 
Given the distance-based weight dij for a given enhancer i and gene isoform j, we defined the 
weight of the corresponding edge in cell type k as:
where the second term is the geometric mean of the normalized activity levels of the 
enhancer and the gene isoform. The activity level of isoforms was defined as the maximum 
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activity level of their promoters (which are usually few — the majority of isoforms have 
only one or two alternative promoters, Supplementary Fig. 6). Accordingly, our confidence 
that an enhancer regulates a gene isoform increases as they are located more closely together 
and have higher joint activity in the given cell type.
Application of this pipeline to the FANTOM5 panel of samples gave rise to 808 regulatory 
circuits. Next, we merged regulatory circuits of closely related samples (Supplementary 
Table 1), such as samples of the same cell or tissue type from different donors and cell lines 
from the same cancer subtype, by taking the graph union (this amounts to taking the union 
of the node and edge sets, while retaining the maximum weight for each edge). The resulting 
394 cell type and tissue-specific regulatory circuits constitute the basis of our analysis 
(corresponding sample annotations are provided in Supplementary Table 1). Note that the 
samples being merged were typically very similar to each other: if one of them was left out, 
on average 94% of edges in the final network remained the same (Supplementary Figs. 4, 5).
We kept our approach to reconstruct regulatory circuits deliberately simple, making it 
generally applicable: here we used CAGE-defined enhancers and promoters from FANTOM, 
but the same approach could directly be applied to chromatin-defined enhancers and 
promoters, for instance. Future work will show if performance can be improved by 
implementing more sophisticated inference algorithms28,47 for specific steps, e.g., to infer 
the target regulatory elements of TFs or to infer the target genes of enhancers.
Positional enrichment of motif instances and regulatory elements
Positional enrichment of TF motif instances near CAGE-defined promoters (Supplementary 
Fig. 1a) was computed as follows. First, a window of 10kb was defined around each 
promoter, and the distance of each motif instance within this window to the promoter was 
evaluated. Distance was defined as the number of base pairs separating the motif from the 
promoter, with the sign indicating whether the motif was located up or downstream from the 
promoter (negative: upstream; positive: downstream; zero: the two elements overlap). The 
empirical distribution of motif–promoter distances was computed using a bin size of 50bp. 
Note that only promoters of genes with a single TSS were considered (to avoid potential bias 
due to nearby TSSs of isoforms). Second, a background distribution was computed by 
shuffling motif instances within the region defined by the union of all promoter-centric 
windows. The resulting motif–promoter distances and corresponding distance distribution 
were evaluated as described. This procedure was repeated 100 times, leading to a very 
precise estimate of the background distribution due to the large number of motif instances 
and promoters. Finally, positional enrichment of motifs was defined as the ratio of the actual 
distance distribution to the background distance distribution. The entire analysis was 
performed independently for motif instances of distinct confidence scores (0.1, 0.2, …, 1.0). 
All operations on genomic elements (overlap, distance, union, shuffling, etc.) were 
performed using the BEDOPS toolkit48.
The same approach was used to compute positional enrichment of TF motif instances near 
CAGE-defined enhancers (Supplementary Fig. 1b) and of CAGE-defined promoters near 
TSSs (Supplementary Fig. 1c). For the former, there is a slight difference because enhancers 
have no orientation (i.e., no negative distance values for upstream location). Note that only 
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enhancers located over 10kb away from any known TSS in Ensembl were considered to 
avoid potential bias due to nearby promoters.
Validation of TF–enhancer and TF–promoter edges using ChIP-seq data
Edges between TFs and regulatory elements (enhancers and promoters) were assessed using 
ChIP-seq data from ENCODE43 in five cell lines that are also present in our library 
(Supplementary Table 2). Besides from our method to infer edges described above, which 
weights edges based on motif confidence and regulatory element expression, we also 
assessed three alternative inference approaches: (1) standard network inference based on 
expression correlation28 (edges are weighted using Spearman correlation between TF 
expression and regulatory element expression across samples), (2) TF motifs alone (edges 
are weighted based on motif confidence), and (3) both TF motifs and expression correlation 
(edges are weighted based on correlation and filtered for those containing at least one motif 
instance of the given TF at the target regulatory element).
For each TF and cell line where ChIP-seq data was available, we assessed inferred TF–target 
edges using the area under the precision–recall curve28,47 (AUPR, see discussion of this 
choice below). Edges were considered positives if they were supported by TF binding (i.e., 
there is a ChIP-seq peak of the TF overlapping the target regulatory element) and negatives 
otherwise. It should be kept in mind that ChIP-seq is an imperfect gold standard and some 
edges may thus be incorrectly labeled as negatives (binding was not detected) or positives 
(non-specific or non-functional binding). The AUPR was computed separately for TF–
enhancer and TF–promoter edges.
As a reference, we further computed the AUPR for: (i) random data, obtained by shuffling 
the ChIP peaks of a given TF within the bound regions (the union of ChIP peaks from all 
TFs) and (ii) ChIP-seq replicates (edges defined by the first replicate were assessed using the 
second replicate and vice-versa). The AUPR values for random data and ChIP-seq replicates 
represent lower and upper bounds for the expected performance of inference methods.
We chose to report the AUPR for TF–target edges (and also enhancer–gene edges, see next 
section) in the main text because it is a standard metric in the field of network inference, 
e.g., it is used in the DREAM network inference challenges to assess predictions28,47. Note 
that because of class imbalance — there are few positives (true edges) compared to negatives 
(absent edges) — the AUPR is better suited as performance metric than the area under the 
receiver operator characteristic (ROC) curve49. Similar results were obtained using the F-
score as performance metric (Supplementary Fig. 12).
Validation of enhancer–gene edges using eQTL data
Edges between enhancers and genes were assessed using cis-eQTLs from GTEx29 in 13 
tissues that are also present in our library (Supplementary Table 3; GTEx data was not used 
to construct the regulatory circuits, see discussion below). In addition to our method 
described above, which links enhancers to target genes based on their genomic distance and 
joint activity in the given tissue, we also assessed two alternative approaches: (1) link 
enhancers to the closest gene (minimum genomic distance) and (2) link enhancers to the 
most strongly correlated gene (maximum Spearman correlation of enhancer and gene 
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expression across samples). For each of these methods, only genes within 500kb from the 
enhancer were considered. As a reference, we further assessed the performance for random 
predictions (linking enhancers to randomly selected genes within the given window of 
500kb).
For each tissue where eQTLs were available, we assessed the inferred enhancer–gene edges 
using the AUPR and F-score (same approach as for TF edges, see previous section). Only 
enhancers that contain at least one eQTL were considered. We defined edges as positives if 
they were confirmed by an eQTL (i.e., the enhancer contains an eQTL for this target gene) 
and negatives otherwise. As mentioned above, both ChIP-seq and eQTLs are imperfect gold 
standards and may thus contain incorrectly labeled edges. In particular, the eQTLs from 
GTEx are known to be largely incomplete as they were called using only ~100 samples per 
tissue29.
Of note, the tissue-specific eQTLs from GTEx used for validation are independent from our 
regulatory circuits, where enhancers were linked to target genes solely based on their 
distance and joint tissue-specific activity (possible eQTLs of a given enhancer were never 
used to determine its targets). The weighting function used for the distance (Supplementary 
Fig. 1d) is the same for all enhancers and tissues and was derived from a different eQTL 
dataset (RegulomeDB46), which does not include GTEx tissues.
Correlation between regulatory edge strength and target gene expression level
We assessed whether incoming regulatory edges of a gene are predictive of its expression 
level using RNA-seq data from the Roadmap Epigenomics project30 in 40 cell types and 
tissues that are also present in our library (Supplementary Table 4). First, we defined the 
gross TF input of a gene as its weighted indegree in the given tissue, i.e., the sum of the 
weights of all incoming TF edges (TF–gene edges are given by the coarse-grained networks 
defined in the next section). For each gene, the correlation coefficient between its TF input 
and expression level (RPKM value) was computed across the 40 tissues (Supplementary Fig. 
13).
Hierarchical clustering of regulatory networks
First, we derived a coarse-grained TF–gene network from each cell type or tissue-specific 
regulatory circuit. TF–gene networks are useful for high-level analyses where we are most 
interested in the TFs regulating each gene, and not the detailed and often redundant wiring 
of these interactions at the level of enhancers, promoters, and isoforms. They also have the 
advantage of being smaller, and thus computationally more amenable, than the fine-grained 
circuits. TF–gene networks were defined as follows. First, we created a network 
encapsulating all regulatory interactions via promoters. For each pair of edges forming a 
chain that connects a TF to a promoter to an isoform, i.e., edges (TFi, promoterj) and 
(promoterj, isoformk) with weights wij and wjk, a corresponding edge (TFi, genel) with 
weight wil = wij wjk was added to the TF–gene network (where isoformk belongs to genel). 
If several redundant edges between the same TF and gene were found (via different 
promoters or isoforms), they were merged and the maximum edge weight was retained. A 
separate TF–gene network encapsulating all regulatory interactions via enhancers was 
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created using the same approach. Both TF–gene networks thus have edge weights ranging 
from zero (absent edge) to one (highest confidence), which were added to form a combined 
TF–gene network including evidence from both promoters and enhancers.
Pairwise similarity of regulatory networks was defined based on similarity of the two edge 
sets. For unweighted networks, the Jaccard index can be used for this purpose (size of the 
intersection divided by size of the union). Here, we used an extension of the Jaccard index 
defined as:
where a and b are the edge weight vectors of the two networks (elements ai and bi giving the 
weights of corresponding edges [connecting the same TF and gene] in the two networks; if 
the edge is not present in one of the networks, the weight is zero). Note that for unweighted 
networks (edge weights equal zero or one), this definition is equivalent to the Jaccard index. 
We used the difference function 1 − f for the hierarchical clustering of the 394 regulatory 
networks because we empirically found that it resulted in more homogeneous clusters than 
Eucledian distance, for instance. We also systematically tested clusters of networks defined 
by a given dendrogram cutoff for enriched sample annotations (Supplementary Figs. 14–24). 
To this end, FANTOM5 sample annotations from the Cell Ontology (CL), Anatomical 
Ontology (UBERON), and Disease Ontology (DOID) were propagated to the corresponding 
networks and each cluster was tested for enriched terms (hypergeometric test, FDR was 
controlled using Benjamini–Hochberg procedure).
The high-level networks corresponding to the 32 clusters defined in Supplementary Fig. 14 
were formed by taking the union of the individual networks within each cluster, retaining 
always the maximum edge weights (i.e., same approach as described above for merging 
regulatory circuits of closely related samples). The same approach was also used to create a 
global regulatory network by taking the union of all 394 cell type and tissue-specific 
networks.
GWAS summary statistics and computation of gene-level p-values
We obtained SNP-phenotype association summary statistics for a comprehensive collection 
of 37 GWASs including psychiatric50–53, neurodegenerative39,54,55, immune-related56–60, 
cardiovascular61,62, blood lipid63,64, glycemic65–70, anthropometric71,72 and other traits73,74 
(Supplementary Table 5). Most of these studies are well-powered meta-analyses: the average 
sample size is over 50,000 individuals with about a third having over 100,000 individuals. 
The average number of SNPs is over 2,2 million.
Since we did not have access to genotype data for most studies, we used LD information 
from a reference population (the European panel of the 1000 genomes project75 [1KG]) to 
summarize SNP association p-values at the level of genes using a similar approach as 
implemented by the popular VEGAS tool76. (We used the summary statistics as provided by 
the original studies, i.e., some studies are not 1KG-imputed, which is not critical to 
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summarize the signal at the level of genes). Briefly, SNPs in the vicinity of a gene were 
aggregated using either the maximum or sum of chi-square statistics, which measure the 
strongest and the average association signal per gene, respectively. (Multiple isoforms of the 
same gene were merged because, due to LD, the resolution of GWAS is typically too low to 
differentiate between individual isoforms of a gene). We found that VEGAS, which relies on 
costly Monte Carlo simulations to estimate p-values for these statistics, was not well suited 
for the high-powered GWASs in our collection (266 hours run time to estimate genome-wide 
p-values down to 10−6 for a 1KG-imputed study). We thus developed a novel approach 
called Pascal (Pathway scoring algorithm), which leverages analytic solutions offering 
dramatic increase in both speed and precision (1.7 hours run time to estimate genome-wide 
p-values down to 10−15). The Pascal tool is described in detail elsewhere41. Here, we applied 
Pascal to define gene-level p-values for all 37 GWASs using default parameters. Results 
reported in this paper are based on the maximum of chi-square statistic; similar results were 
obtained using the sum of chi-square statistic.
Network connectivity enrichment analysis
Given a network and summary statistics from a GWAS, our aim is to evaluate whether genes 
perturbed by trait-associated variants are more densely interconnected than expected. We 
refer to such groups of densely interconnected nodes as network modules. (Here we only 
evaluate the degree to which trait-associated genes cluster in modules — we do not identify 
discrete modules or pathways). An overview of the four steps of the approach is given in 
Supplementary Fig. 27.
The first step is to aggregate GWAS summary statistics at the level of genes, as described in 
the previous section.
The second step is to define how “close” any two genes are in the network. The 
directionality of links is not considered for this purpose: for example, two genes that are co-
regulated by a TF gene may be considered “close” because they are connected through this 
TF, and two TF genes that regulate the same target gene could be considered “close” 
because they are connected through this target gene. Shortest path length is sometimes used 
to define “closeness”, but is not very informative for biological networks because the 
shortest path between any two nodes is typically short due to the presence of hubs. An 
alternative approach is to use diffusion kernels on graphs77, where “closeness” (hereafter 
referred to as connectivity) between two genes is defined based on the probability that a 
random walk on the graph leads from one gene to the other. This approach naturally captures 
the hierarchical modular structure of biological networks (genes in the same module have 
higher probability to be connected by a random walk). Here, we used a weighted p-step 
random-walk kernel78 to define the pairwise connectivity between nodes:
where I is the identity matrix, W is the weighted adjacency matrix of the graph (entry wij is 
the weight of the edge between nodes i and j, entries on the diagonal are set to zero), D is the 
degree matrix of the graph (a diagonal matrix where entry dii is the degree of node i), and p 
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is the number of steps in the random walk (we used p=4 because biological networks are 
typically shallow and we expect few meaningful interactions over paths longer than four). 
Note that K can be computed cheaply because W is sparse. As mentioned above, the 
directionality of links was not considered for the purpose of defining pairwise connectivity, 
i.e., W and K are both symmetric (thus, co-regulated genes are connected trough their shared 
regulators and tend to have high pairwise connectivity, in particular if they are part of a 
regulatory module with multiple shared regulators [i.e, many possible random walks 
connecting them]).
The third step is to compute connectivity enrichment curves. To this end, genes were ranked 
by their GWAS p-value, from most to least significant. For each position n in the ranked list 
(n = 1, 2, …, N, where N is the number of genes), the connectivity between the top n genes 
was defined as the mean of their pairwise connectivity values kij (gene pairs in LD were 
excluded, see below). Next, the connectivity between the top n genes was computed in the 
same way for 10,000 permutations of the ranked gene list. Importantly, only labels of genes 
with similar network centrality were permuted among each other (the centrality of a gene 
was defined as its mean pairwise connectivity with all other genes). Specifically, genes were 
separated into 100 bins based on their centrality, and only labels within the same bin were 
shuffled (a similar approach, within-degree gene label permutation, is commonly used in 
network-based GWAS analysis11,79; Supplementary Fig. 30). Finally, the connectivity 
enrichment curve was computed as the ratio of the observed connectivity between the top n 
genes to the median connectivity between the top n genes across the 10,000 permutations, 
for each position n in the ranked list.
The fourth step is to summarize the connectivity enrichment curves by the signed area under 
the curve. This is done both for the original data and the 10,000 permutations, enabling the 
computation of a corresponding empirical p-value. Finally, the connectivity enrichment 
score for the given GWAS and network is defined as the negative log10 of the empirical p-
value.
Note that the connectivity between neighboring genes on the genome was excluded from this 
analysis (Supplementary Fig. 29). This is important because, on the one hand, the GWAS 
association signal of neighboring genes is often correlated due to LD, and on the other hand, 
neighboring genes are often also functionally related or co-regulated (i.e., they may also be 
neighbors at the network level). To ensure that such groups of correlated and functionally 
related genes did not inflate connectivity enrichment, we took a conservative approach and 
completely excluded the connectivity between all neighboring genes (distance < 1mb) from 
the network connectivity enrichment analysis (the corresponding entries in the connectivity 
matrix K were set to NA (not available), i.e., they were ignored in all calculations). Since the 
human leukocyte antigen (HLA) genes form an exceptionally large cluster that also shows 
strong association with many immune-related traits, we further completely excluded all 
genes in the HLA region. Taken together, this ensures that the observed network 
connectivity enrichment is not driven by the HLA genes or similar gene clusters.
We confirmed using phenotype-label permutations that our method corrects for LD structure 
and other potential confounders (Supplementary Fig. 30).
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Assessment of other network types
Besides from our cell type and tissue-specific regulatory networks, we also assessed 
connectivity enrichment for five other types of networks. We only considered molecular 
networks derived from experimental data, not functional networks that were mined from the 
literature (e.g., co-citation networks).
First, we generated a global co-expression network from the FANTOM5 data23 (i.e., the 
same dataset that was used to construct the regulatory circuits). To this end, gene expression 
levels were defined as the sum of the corresponding promoter expression levels. TF–gene 
edge weights were computed using Spearman correlation and the top 100k edges were 
retained.
Second, we obtained 35 tissue-specific co-expression networks from Piersen et al.15 These 
networks were inferred from GTEx data29 using an algorithm that shares information 
between related tissues.
Third, we collected four well-established protein-protein interaction networks: (1) the InWeb 
protein interaction database developed by Lage et al.80 and used by the popular DAPPLE 
tool11 probabilistically integrates evidence from diverse sources, including MINT, BIND, 
IntAct, KEGG annotated protein-protein interactions (PPrel), KEGG Enzymes involved in 
neighboring steps (ECrel), Reactome and others; (2) Entrez GeneRIF (gene reference into 
function) includes protein interactions from BIND, BioGRID, HPRD and other sources81; 
(3) the BioGRID database provides literature-curated protein interactions82; and (4) the 
Human Interactome project is systematically screening the human proteome for interactions 
using yeast two-hybrid and other assays83.
Fourth, we obtained a global regulatory network from Gerstein et al.17 The network is based 
on ChIP-seq data from ENCODE.
Fifth, we considered 41 tissue-specific regulatory networks based on DNaseI footprints from 
Neph et al.42 Of note, these networks only comprise TF–TF edges, i.e., edges between TFs 
and target genes that are not TFs themselves have not been included.
Identification of trait-relevant regulatory networks
A possible approach to identify trait-relevant cell type and tissue-specific networks would be 
to perform connectivity enrichment analysis exhaustively for all 37 traits and 394 regulatory 
networks in our library (i.e, ~15,000 trait–network combinations). However, this is not 
practical because of the resulting multiple testing burden and compute time (a single run 
with 10,000 permutations takes about 15 minutes, depending on the network size). Thus, we 
leveraged the fact that related networks are often very similar and exhaustively tested 
connectivity enrichment only for the 32 high-level networks across all traits (FDR was 
controlled using Benjamini–Hochberg procedure). Subsequently, for each trait, we only 
tested connectivity enrichment for individual cell type and tissue-specific networks 
belonging to high-level networks that had shown connectivity enrichment with score > 1.0 
for this trait (i.e., 10% FDR). We deliberately chose a permissive threshold because cell-
type-specific modules may be “diluted” in the high-level networks by links from other cell 
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types or tissues, which could weaken the observed connectivity enrichment in high-level 
networks.
Availability of networks, data, tools and source code
We provide all networks, supplementary data, and code along with a user-friendly desktop 
app on our website: http://regulatorycircuits.org. In addition, the networks and 
supplementary data have been deposited on an external repository for biomedical data 
(Synapse84) and code has been deposited on GitHub. Links to these resources are available 
on our website and in Supplementary Table 6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Pouya Kheradpour for providing the collection of curated TF binding motifs, Virginia Gao and Fred 
Marbach for comments on the manuscript, and Lajos Szeles for comments on immune-related results. ZK received 
financial support from the Leenaards Foundation, the Swiss Institute of Bioinformatics, and the Swiss National 
Science Foundation (31003A-143914, 51RTP0_151019). SB received funding from the Swiss Institute of 
Bioinformatics, the Swiss National Science Foundation (grant FN 310030_152724 / 1), and SystemsX.ch through 
the SysGenetiX project.
References
1. Marstrand TT, Storey JD. Identifying and mapping cell-type-specific chromatin programming of 
gene expression. Proc. Natl. Acad. Sci. 2014; 111:E645–E654. [PubMed: 24469817] 
2. Pers TH, et al. Biological interpretation of genome-wide association studies using predicted gene 
functions. Nat. Commun. 2015; 6:5890. [PubMed: 25597830] 
3. Roy S, et al. A predictive modeling approach for cell line-specific long-range regulatory 
interactions. Nucleic Acids Res. 2015; 43:8694–8712. [PubMed: 26338778] 
4. Ward LD, Kellis M. Interpreting noncoding genetic variation in complex traits and human disease. 
Nat. Biotechnol. 2012; 30:1095–1106. [PubMed: 23138309] 
5. Parker SCJ, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor 
human disease risk variants. Proc. Natl. Acad. Sci. 2013; 110:17921–17926. [PubMed: 24127591] 
6. Trynka G, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. 
Nat. Genet. 2013; 45:124–130. [PubMed: 23263488] 
7. Faye LL, Machiela MJ, Kraft P, Bull SB, Sun L. Re-ranking sequencing variants in the post-GWAS 
era for accurate causal variant identification. PLoS Genet. 2013; 9:e1003609. [PubMed: 23950724] 
8. Pickrell JK. Joint analysis of functional genomic data and genome-wide association studies of 18 
human traits. Am. J. Hum. Genet. 2014; 94:559–573. [PubMed: 24702953] 
9. Pasquali L, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated 
variants. Nat. Genet. 2014; 46:136–143. [PubMed: 24413736] 
10. Navlakha S, Kingsford C. The power of protein interaction networks for associating genes with 
diseases. Bioinforma. Oxf. Engl. 2010; 26:1057–1063.
11. Rossin EJ, et al. Proteins encoded in genomic regions associated with immune-mediated disease 
physically interact and suggest underlying biology. PLoS Genet. 2011; 7:e1001273. [PubMed: 
21249183] 
12. Chen Y, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008; 
452:429–435. [PubMed: 18344982] 
Marbach et al. Page 15
Nat Methods. Author manuscript; available in PMC 2016 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
13. Lee I, Blom UM, Wang PI, Shim JE, Marcotte EM. Prioritizing candidate disease genes by 
network-based boosting of genome-wide association data. Genome Res. 2011; 21:1109–1121. 
[PubMed: 21536720] 
14. Mäkinen V-P, et al. Integrative genomics reveals novel molecular pathways and gene networks for 
coronary artery disease. PLoS Genet. 2014; 10:e1004502. [PubMed: 25033284] 
15. Pierson E, Koller D, Battle A, Mostafavi S, the GTEx Consortium. Sharing and Specificity of Co-
expression Networks across 35 Human Tissues. PLoS Comput Biol. 2015; 11:e1004220. 
[PubMed: 25970446] 
16. Greene CS, et al. Understanding multicellular function and disease with human tissue-specific 
networks. Nat. Genet. 2015; 47:569–576. [PubMed: 25915600] 
17. Gerstein MB, et al. Architecture of the human regulatory network derived from ENCODE data. 
Nature. 2012; 489:91–100. [PubMed: 22955619] 
18. Marbach D, et al. Predictive regulatory models in Drosophila melanogaster by integrative inference 
of transcriptional networks. Genome Res. 2012; 22:1334–1349. [PubMed: 22456606] 
19. Karczewski KJ, Snyder M, Altman RB, Tatonetti NP. Coherent functional modules improve 
transcription factor target identification, cooperativity prediction, and disease association. PLoS 
Genet. 2014; 10:e1004122. [PubMed: 24516403] 
20. Boyer LA, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 
2005; 122:947–956. [PubMed: 16153702] 
21. Ciofani M, et al. A validated regulatory network for th17 cell specification. Cell. 2012; 151:289–
303. [PubMed: 23021777] 
22. Chen JC, et al. Identification of causal genetic drivers of human disease through systems-level 
analysis of regulatory networks. Cell. 2014; 159:402–414. [PubMed: 25303533] 
23. The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian 
expression atlas. Nature. 2014; 507:462–470. [PubMed: 24670764] 
24. Andersson R, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014; 
507:455–461. [PubMed: 24670763] 
25. Califano A, Butte AJ, Friend S, Ideker T, Schadt E. Leveraging models of cell regulation and 
GWAS data in integrative network-based association studies. Nat. Genet. 2012; 44:841–847. 
[PubMed: 22836096] 
26. Kheradpour P, et al. Systematic dissection of regulatory motifs in 2000 predicted human enhancers 
using a massively parallel reporter assay. Genome Res. 2013; 23:800–811. [PubMed: 23512712] 
27. Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory motifs in 
ENCODE TF binding experiments. Nucleic Acids Res. 2014; 42:2976–2987. [PubMed: 
24335146] 
28. Marbach D, et al. Wisdom of crowds for robust gene network inference. Nat. Methods. 2012; 
9:796–804. [PubMed: 22796662] 
29. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene 
regulation in humans. Science. 2015; 348:648–660. [PubMed: 25954001] 
30. Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference human epigenomes. 
Nature. 2015; 518:317–330. [PubMed: 25693563] 
31. Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol. 
2014; 2:581–592. [PubMed: 24731664] 
32. Perez-Costas E, Melendez-Ferro M, Roberts RC. Basal ganglia pathology in schizophrenia: 
dopamine connections and anomalies. J. Neurochem. 2010; 113:287–302. [PubMed: 20089137] 
33. Garrett A, Chang K. The role of the amygdala in bipolar disorder development. Dev. Psychopathol. 
2008; 20:1285–1296. [PubMed: 18838042] 
34. Cromer WE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS. Role of the endothelium in 
inflammatory bowel diseases. World J. Gastroenterol. WJG. 2011; 17:578–593. [PubMed: 
21350707] 
35. Swirski FK, et al. Identification of Splenic Reservoir Monocytes and Their Deployment to 
Inflammatory Sites. Science. 2009; 325:612–616. [PubMed: 19644120] 
Marbach et al. Page 16
Nat Methods. Author manuscript; available in PMC 2016 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
36. Chichlowski M, Westwood GS, Abraham SN, Hale LP. Role of mast cells in inflammatory bowel 
disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PloS One. 2010; 
5:e12220. [PubMed: 20808919] 
37. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. 
Nat. Rev. Rheumatol. 2014; 10:593–601. [PubMed: 24914698] 
38. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. 
Neurosci. 2004; 5:347–360. [PubMed: 15100718] 
39. Hor H, et al. Genome-wide association study identifies new HLA class II haplo-types strongly 
protective against narcolepsy. Nat. Genet. 2010; 42:786–789. [PubMed: 20711174] 
40. Goodrich JK, et al. Human genetics shape the gut microbiome. Cell. 2014; 159:789–799. 
[PubMed: 25417156] 
41. Lamparter D, Marbach D, Rico R, Kutalik Z, Bergmann S. Fast and rigorous computation of gene 
and pathway scores from SNP-based summary statistics. PLoS Comp Bio. in press. 
42. Neph S, et al. Circuitry and Dynamics of Human Transcription Factor Regulatory Networks. Cell. 
2012; 150:1274–1286. [PubMed: 22959076] 
43. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human 
genome. Nature. 2012; 489:57–74. [PubMed: 22955616] 
44. Arner E, et al. Transcribed enhancers lead waves of coordinated transcription in transitioning 
mammalian cells. Science. 2015:1259418. doi:10.1126/science.1259418. 
45. Kheradpour P, Stark A, Roy S, Kellis M. Reliable prediction of regulator targets using 12 
Drosophila genomes. Genome Res. 2007; 17:1919–1931. [PubMed: 17989251] 
46. Boyle AP, et al. Annotation of functional variation in personal genomes using RegulomeDB. 
Genome Res. 2012; 22:1790–1797. [PubMed: 22955989] 
47. Marbach D, et al. Revealing strengths and weaknesses of methods for gene network inference. 
Proc. Natl. Acad. Sci. U. S. A. 2010; 107:6286–6291. [PubMed: 20308593] 
48. Neph S, et al. BEDOPS: high-performance genomic feature operations. Bioinformatics. 2012; 
28:1919–1920. [PubMed: 22576172] 
49. Davis, J.; Goadrich, M. ICML '06: Proceedings of the 23rd international conference on Machine 
learning. ACM; 2006. The relationship between Precision-Recall and ROC curves; p. 
233-240.athttp://dx.doi.org/10.1145/1143844.1143874
50. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 
108 schizophrenia-associated genetic loci. Nature. 2014; 511:421–427. [PubMed: 25056061] 
51. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with 
shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 
381:1371–1379. [PubMed: 23453885] 
52. Ripke S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. 
Genet. 2013; 45:1150–1159. [PubMed: 23974872] 
53. Boraska V, et al. A genome-wide association study of anorexia nervosa. Mol. Psychiatry. 2014; 
19:1085–1094. [PubMed: 24514567] 
54. Lambert J-C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for 
Alzheimer's disease. Nat. Genet. 2013; 45:1452–1458. [PubMed: 24162737] 
55. Simón-Sánchez J, et al. Genome-wide association study reveals genetic risk underlying Parkinson's 
disease. Nat. Genet. 2009; 41:1308–1312. [PubMed: 19915575] 
56. International Multiple Sclerosis Genetics Consortium. et al. Genetic risk and a primary role for 
cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476:214–219. [PubMed: 
21833088] 
57. Anderson CA, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the 
number of confirmed associations to 47. Nat. Genet. 2011; 43:246–252. [PubMed: 21297633] 
58. Franke A, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's 
disease susceptibility loci. Nat. Genet. 2010; 42:1118–1125. [PubMed: 21102463] 
59. Stahl EA, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid 
arthritis risk loci. Nat. Genet. 2010; 42:508–514. [PubMed: 20453842] 
Marbach et al. Page 17
Nat Methods. Author manuscript; available in PMC 2016 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
60. Rauch A, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment 
Failure: A Genome-Wide Association Study. Gastroenterology. 2010; 138:1338–1345.e7. 
[PubMed: 20060832] 
61. Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for 
coronary artery disease. Nat. Genet. 2011; 43:333–338. [PubMed: 21378990] 
62. The International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic 
variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 
478:103–109. [PubMed: 21909115] 
63. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. 
Nat. Genet. 2013; 45:1274–1283. [PubMed: 24097068] 
64. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. 
Nature. 2010; 466:707–713. [PubMed: 20686565] 
65. Prokopenko I, et al. A Central Role for GRB10 in Regulation of Islet Function in Man. PLoS 
Genet. 2014; 10:e1004235. [PubMed: 24699409] 
66. The DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale 
association analysis provides insights into the genetic architecture and pathophysiology of type 2 
diabetes. Nat. Genet. 2012; 44:981–990. [PubMed: 22885922] 
67. Scott RA, et al. Large-scale association analyses identify new loci influencing glycemic traits and 
provide insight into the underlying biological pathways. Nat. Genet. 2012; 44:991–1005. 
[PubMed: 22885924] 
68. Soranzo N, et al. Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via 
Glycemic and Nonglycemic Pathways. Diabetes. 2010; 59:3229–3239. [PubMed: 20858683] 
69. Dupuis J, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on 
type 2 diabetes risk. Nat. Genet. 2010; 42:105–116. [PubMed: 20081858] 
70. Strawbridge RJ, et al. Genome-Wide Association Identifies Nine Common Variants Associated 
With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2. 
Diabetes. 2011; 60:2624–2634. [PubMed: 21873549] 
71. Lango Allen H, et al. Hundreds of variants clustered in genomic loci and biological pathways 
affect human height. Nature. 2010; 467:832–838. [PubMed: 20881960] 
72. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with 
body mass index. Nat. Genet. 2010; 42:937–948. [PubMed: 20935630] 
73. The AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. 
Nat. Genet. 2013; 45:433–439. [PubMed: 23455636] 
74. Estrada K, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 
loci associated with risk of fracture. Nat. Genet. 2012; 44:491–501. [PubMed: 22504420] 
75. Clarke L, et al. The 1000 Genomes Project: data management and community access. Nat. 
Methods. 2012; 9:459–462. [PubMed: 22543379] 
76. Liu JZ, et al. A versatile gene-based test for genome-wide association studies. Am. J. Hum. Genet. 
2010; 87:139–145. [PubMed: 20598278] 
77. Kondor, RI.; Lafferty, JD. Proceedings of the Nineteenth International Conference on Machine 
Learning. Morgan Kaufmann Publishers Inc; 2002. Diffusion Kernels on Graphs and Other 
Discrete Input Spaces; p. 315-322.athttp://dl.acm.org/citation.cfm?id=645531.655996
78. Smola, AJ.; Kondor, R. Learning Theory and Kernel Machines. Schölkopf, B.; Warmuth, MK., 
editors. Springer Berlin Heidelberg; 2003. p. 144-158.athttp://link.springer.com/chapter/
10.1007/978-3-540-45167-9_12
79. Erten S, Bebek G, Ewing RM, Koyutürk M. DADA: Degree-Aware Algorithms for Network-Based 
Disease Gene Prioritization. BioData Min. 2011; 4:19. [PubMed: 21699738] 
80. Lage K, et al. A human phenome-interactome network of protein complexes implicated in genetic 
disorders. Nat. Biotechnol. 2007; 25:309–316. [PubMed: 17344885] 
81. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. 
Nucleic Acids Res. 2011; 39:D52–D57. [PubMed: 21115458] 
82. Chatr-Aryamontri A, et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 
2015; 43:D470–D478. [PubMed: 25428363] 
Marbach et al. Page 18
Nat Methods. Author manuscript; available in PMC 2016 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
83. Rolland T, et al. A proteome-scale map of the human interactome network. Cell. 2014; 159:1212–
1226. [PubMed: 25416956] 
84. Derry JMJ, et al. Developing predictive molecular maps of human disease through community-
based modeling. Nat. Genet. 2012; 44:127–130. [PubMed: 22281773] 
Marbach et al. Page 19
Nat Methods. Author manuscript; available in PMC 2016 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Inference of regulatory circuits and connectivity between trait-associated genes
(a) The resource of 394 cell type and tissue-specific regulatory circuits is based on 
expression profiles of CAGE-defined enhancers and promoters from the FANTOM5 
project23,24. Weighted, tissue-specific links between TFs and regulatory elements (enhancers 
and promoters) are inferred using TF binding motifs and tissue-specific expression of target 
elements. Links between regulatory elements and target genes are inferred based on genomic 
distance and joint expression in the given tissue. Different circuit configurations are shown 
schematically for five tissues. For clarity only one enhancer and promoter are shown, but 
genes typically have multiple tissue-specific enhancers and promoters. (b) In order to 
summarize which TFs regulate which genes, we also define coarse-grained TF–gene 
networks that encapsulate the fine-grained circuitry of enhancers and promoters. (c) We 
systematically assess the interconnectivity of genes that are perturbed by trait-associated 
variants within our networks for a large panel of 37 GWASs. Our pipeline first integrates 
GWAS summary statistics at the level of genes using Pascal41, a tool that accurately corrects 
for confounders such as linkage disequilibrium, and then evaluates whether top ranked genes 
tend to cluster in network modules based on a random-walk graph kernel (connectivity 
enrichment analysis, Methods and Supplementary Figs. 27–30). Importantly, this approach 
does not use a cutoff for the GWAS p-values and thus also assesses the contribution of 
weakly associated variants. We apply this pipeline to pinpoint cell type or tissue-specific 
regulatory networks where modules are perturbed for different traits and diseases.
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Figure 2. Assessment of regulatory circuits
(a) Evaluation of different approaches to infer edges between TFs and regulatory elements 
(enhancers and promoters): (1) standard network inference based on expression correlation 
between TFs and regulatory elements across samples; (2) presence of TF motifs within 
regulatory elements; (3) presence of TF motifs, weighted by expression correlation; and (4) 
presence of TF motifs, weighted by target element expression in the given cell type (the 
retained method to reconstruct regulatory circuits). For each TF and cell type where ChIP-
seq data was available (159 samples, including 59 TFs and five cell lines), the area under the 
precision-recall curve (AUPR) was computed. As reference, AUPR values were also 
computed for (i) random data and (ii) replicates of ChIP-seq experiments. Boxplots show the 
distribution of AUPR values for each method. The retained method (*) achieves a median 
AUPR of 0.51, which is significantly better than alternative methods (p < 10−15, one-sided 
Wilcoxon rank-sum test) and the performance is close to that of of ChIP-seq replicates 
(median AUPR=0.64). (b) Assessment of different approaches to link enhancers to target 
genes: (1) maximum expression correlation across tissues (assign enhancer to most strongly 
correlated gene within 500kb); (2) minimum genomic distance (assign enhancer to closest 
gene); and (3) joint tissue-specific activity (defined as geometric mean of enhancer and gene 
expression) weighted by genomic distance (the retained method to construct regulatory 
circuits). AUPR was evaluated for each method as well as random predictions in 13 tissues 
where eQTL data were available. The retained method (*) has a median AUPR of 0.33, 
which is significantly better than alternative methods (p < 0.05, one-sided Wilcoxon rank-
sum test). Of note, AUPR values are only comparable within each panel, not across panels 
(a) and (b) because the underlying gold standards are different (Methods). (c) Evaluation of 
whether trait-associated genes tend to cluster within modules for different types of networks 
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and GWAS traits. Five types of networks are compared: (1) cell type and tissue-specific 
regulatory networks (the 32 high-level networks defined in Supplementary Fig. 14), (2) four 
protein-protein interaction networks, (3) 35 tissue-specific co-expression networks15, (4) a 
global co-expression network inferred from the FANTOM5 data, and (5) a global regulatory 
network based on ChIP-seq17 (Methods). In addition, tissue-specific regulatory networks 
based on DNaseI footprints42 were assessed, but did not show any significant enrichment. 
The plot summarizes whether trait-associated genes are more densely interconnected than 
expected (maximum connectivity enrichment score) for each network type (row) and trait 
(column). The scores correspond to the negative log of the q-values. (False discovery rate 
(FDR) correction was performed separately for each network type to allow for a fair 
comparison). Rows are ordered based on the overall enrichment (Supplementary Fig. 31a): 
tissue-specific regulatory networks show the strongest connectivity enrichment. Some traits 
did not show significant connectivity enrichment, which may be either because the signal 
was too weak, the relevant tissues were not profiled (e.g., our library does not include 
pancreatic islet cells relevant for type 2 diabetes9), or other types of networks (e.g., post-
transcriptional) may be more relevant for these traits.
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Figure 3. Network connectivity enrichment reveals disease-relevant cell types and tissues
Connectivity enrichment scores across the 32 high-level networks (left; numbers in 
parenthesis correspond to cluster indexes in Supplementary Fig. 14) and corresponding 
individual networks (right) for selected GWAS traits. (Similar results were obtained for the 
remaining traits, see main text and Supplementary Figs. 32–43). Networks of trait-relevant 
cell types and tissues consistently rank at the top, i.e., show strongest clustering of perturbed 
genes. All networks with enrichment scores > 1.0 are shown. (a) Psychiatric disorders show 
strongest clustering of associated genes in regulatory networks of neural tissues, with the 
exception of anorexia nervosa, where we further observe strong signal for tissues of the 
endocrine system (hormonal glands, Supplementary Fig. 14c). For schizophrenia, 
connectivity enrichment is shown both for the high-level networks (left) and the 
corresponding individual networks (right), illustrating how perturbed regulatory modules 
pinpoint specific, disease-relevant brain structures. (b) Inflammatory bowel disease (IBD) 
and rheumatoid arthritis are examples of immune disorders, which display connectivity 
enrichment in immune-related networks. IBD also shows enrichment in other high-level 
networks, most of which include vascular cells that are involved in the inflammatory 
response and are driving the signal, as shown to the right. (c) Alzheimer's disease and 
narcolepsy, two neurodegenerative disorders, show strongest network connectivity 
enrichment in adult brain and neurons, respectively. (d) Age-related macular degeneration 
(AMD) of neovascular type shows the strongest connectivity enrichment in regulatory 
networks of vascular smooth muscle cells followed by diverse tumors, which induce 
vascularization to achieve growth. As a control, we further confirmed that the dry form of 
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AMD, which does not involve neovascularization, does not show any connectivity 
enrichment in these networks.
Marbach et al. Page 24
Nat Methods. Author manuscript; available in PMC 2016 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
